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Summary
Memory B cells are long-lived and could contribute to persistence of
humoral immunity by maintaining the plasma-cell pool or making recall
responses upon re-exposure to an antigen. We determined the ability of a
pneumococcal conjugate vaccine to induce anti-pneumococcal memory B
cells. Frequencies of memory B cells against pneumococcal capsular
polysaccharides from serotypes 1, 6B, 14, 19F and 23F were determined
by cultured B cell enzyme-linked immunospot (ELISPOT) in 35 children
aged 12–23 months who received pneumococcal non-typeable
Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV). The
relationships between plasma antibodies and memory B cell frequencies
were also assessed. After two doses of PHiD-CV, the proportion of
subjects with detectable memory B cells against pneumococcal capsular
polysaccharides increased significantly for serotypes 1 (3–45%; P< 001),
19F (21–66%; P< 001) and 23F (13–36%; P5 002), but not serotypes
6B (24–42%; P5 024) and 14 (21–40%; P5 006). Correlations between
antibodies and memory B cells were weak. Carriage of serotype 19F at
enrolment was associated with poor memory B cell responses against this
serotype at subsequent time-points (day 30: non-carriers, 82% versus
carriers, 0%, P< 001; day 210: non-carriers, 72% versus carriers, 33%,
P5 007). PHiD-CV is capable of inducing memory B cells against some
of the component pneumococcal capsular polysaccharides.
Keywords: children, ELISPOT, memory B cells, PHiD-CV, pneumococcal
conjugate vaccines
Introduction
Streptococcus pneumoniae is a major cause of morbidity
and mortality in the world, accounting for an estimated
478 000 deaths in children below 5 years of age in 2008
[1]. In countries where a pneumococcal conjugate vaccine
has been introduced into the childhood immunization
schedule, a dramatic reduction of the incidence of
vaccine-type invasive pneumococcal disease (IPD) among
vaccinated children has been reported, as has indirect pro-
tection of unvaccinated individuals [2–4]. S. pneumoniae
is a leading cause of invasive bacterial disease in Kenyan
children, and in 2011 the Kenyan Government introduced
Synflorix
VR
, the 10-valent pneumococcal non-typeable
Haemophilus influenzae protein-D conjugate vaccine
(PHiD-CV), into its childhood immunization programme
[5,6]. The pneumococcal capsular polysaccharides in
PHiD-CV are conjugated to protein D of H. influenzae
(serotypes 1, 4, 5, 6B, 7F, 9V, 14 and 23F), tetanus toxoid
(serotype 18C) and diphtheria toxoid (serotype 19F).
The immunogenicity of pneumococcal vaccines has been
assessed by measuring serum immunoglobulin (Ig)G [by
enzyme-linked immunosornebt assay (ELISA)] and opso-
nophagocytic activity (OPA). Studies in Europe, South
America and Asia found comparable immunogenicity of
PHiD-CV and the 7-valent pneumococcal conjugate
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vaccine (PCV7), even when co-administered with other
childhood vaccinations [7–10], leading to licensure of
PHiD-CV in more than 120 countries. Antibody titres and
OPA after vaccination wane over time, but increase mark-
edly after booster vaccination, suggesting that the primary
vaccination induces immunological memory [11].
Memory B cells form an important arm of humoral
immunity, but unlike antibody responses these have not
been investigated previously in the immune response to
PHiD-CV. For most antigens, after an initial antigenic chal-
lenge, both long-lived plasma cells and memory B cells are
generated [12]. Long-lived plasma cells constitutively
secrete antibodies of a given specificity. Memory B cells are
quiescent, but differentiate rapidly into short-lived plasma
cells upon secondary exposure to an antigen, thus boosting
the concentrations of available circulating antibodies
[13,14]. They have also been suggested to play a role in the
maintenance of the plasma cell pool in absence of antigen,
by being either activated polyclonally by pathogen-
associated molecular patterns or bystander T cell help [15].
They can repopulate germinal centres and undergo further
rounds of affinity maturation, resulting in an adapted pop-
ulation of memory and long-lived plasma cells while main-
taining the existing memory B cell population [14].
Memory B cells are maintained in the absence of cognate
antigen, and this characteristic is thought to be responsible
for the protection that is observed after waning of plasma
antibodies to undetectable levels in individuals who are
immunized against hepatitis B [16,17]. Indeed, they have
been shown to protect against Japanese encephalitis in
absence of plasma antibodies and CD81 T cells in mice [18].
Following immunization with serogroup C meningo-
coccal (MenC) glycoconjugate vaccine, the presence of
circulating antibodies, as opposed to memory B cells, is
the main determinant of protection from disease, prob-
ably because clinical disease develops within hours of
infection before immunological recall responses are estab-
lished [19]. However, good memory responses have been
associated with persistence of protective antibodies, sug-
gesting that memory B cells could be indirectly important
in determining the longevity of protection [20].
Assessment of the induction of memory B cells after
vaccination provides important information about the
durability of the immune response and could be a practical
way of assessing the duration of protection. In this study,
we aimed to determine whether vaccination with PHiD-CV
induced a serotype-specific anti-pneumococcal memory B
cell response. We tested this in a study of Kenyan toddlers.
Materials and methods
Study participants
This analysis is a substudy of a double-blind, randomized
controlled trial that evaluated the immunogenicity,
impact on nasopharyngeal carriage and reactogenicity of
PHiD-CV among 600 Kenyan children aged 12–59
months [21]. In a randomly selected subset of 35 children
aged 12–23 months who received PHiD-CV at enrolment
and 6 months later, the frequencies of antigen-specific
memory B cells were assessed on the day of enrolment
before vaccination and 1 month after each dose of PHiD-
CV. Written informed consent was obtained from each
participant’s parent/guardian. The study protocol was
reviewed and approved by the Kenya National Ethical
Review Committee (SSC 1635) and the Oxford Tropical
Ethical Review Committee (no. 54-09).
Cultured B cell enzyme-linked immunospot
(ELISPOT) for determination of frequencies of
antigen-specific memory B cells
Because of the limited amount of blood that could be
obtained from the children, cellular assays were limited to
serotypes 1, 6B, 14, 19F and 23F. These serotypes were
chosen based on their contribution to IPD and nasopha-
ryngeal carriage in the study setting [22,23]. Five ml
blood were collected into sodium heparin tubes on the
day of enrolment (just before the first dose), 30 days after
enrolment (1 month after the first dose) and 210 days
after enrolment (1 month after the second dose). The
samples were then separated into plasma and cellular
fractions by centrifugation. Peripheral blood mononuclear
cells (PBMCs) were isolated by density gradient centrifu-
gation, washed and frozen at 5 3 106 cells/ml in freezing
media comprising 10% dimethylsulphoxide (DMSO)
(Sigma, St Louis, MO, USA) in fetal bovine serum (Invi-
trogen, Carlsbad, CA, USA).
Memory B cells against vaccine antigens were quanti-
fied using the method developed by Crotty et al. [24].
Briefly, PBMCs were thawed, washed and cultured for 6
days in RPMI complete media (RPMI, 10% newborn
bovine serum, 2 mM l-glutamine, 100 units/ml penicillin,
01 mg/ml streptomycin, 10 mM Hepes, 05 mM b-mer-
captoethanol) containing 25 lg/ml cytosine–phosphate–
guanine (CpG) oligodeoxynucleotides (ODN) 2006
(Hycult Biotech, Plymouth Meeting, PA, USA), 1 : 5000
dilution of S. aureus Cowan strain protein A (Sigma) and
0083 lg/ml of pokeweed mitogen (Sigma) at 2 3 105
cells per 200 ll in U-bottomed 96-well culture plates.
ELISPOT multi-screen filter plates (Millipore, Darm-
stadt, Germany) were coated overnight at 48C with either
pneumococcal capsular polysaccharides for serotypes 1
(20 lg/ml), 6B (10 lg/ml), 14 (10 lg/ml), 19F (20 lg/
ml) and 23F (20 lg/ml) (donation from GSK Biologicals,
Rixensart, Belgium) in the presence of 10 lg/ml (1 and
14) or 20 lg/ml (6B, 19F and 23F) methylated human
serum albumin (mHSA). Tetanus toxoid and diphtheria
toxoid were coated at a concentration of 5 lg/ml, whereas
goat anti-human Igs (Caltag, Burlingame, CA, USA) were
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coated at 10 lg/ml. Negative control wells for determina-
tion of background responses were coated with mHSA
alone at 10 lg/ml.
Thereafter, ELISPOT plates were washed three times
with phosphate-buffered saline (PBS) and blocked for at
least 1 h with 10% newborn bovine serum (NBBS) in
PBS. PBMCs harvested from the 6-day cultures were
seeded into the ELISPOT plates at either 200 and 2000
cells/well (total IgG-secreting cells) or at 2 3 105 cells/well
(antigen-specific IgG-secreting cells) and incubated at
378C in 5% carbon dioxide and 95% humidity overnight.
Then, cells were discarded and plates washed four times
with 025% Tween in PBS followed by a 5-min soak with
PBS. Wells were subsequently incubated with 50 ll/well of
alkaline phosphatase-conjugated donkey anti-human IgG
(Jackson ImmunoResearch Laboratories, West Grove, PA,
USA) diluted with 10% NBBS in PBS at a dilution of 1 :
1000. After 4 h, the plates were washed five times with
025% Tween in PBS and then three times with distilled
water. Spots were developed by adding 50 ll/well of alka-
line phosphatase substrate (Bio-Rad, Hercules, CA, USA).
The reaction was stopped by washing with distilled water.
The plates were left to dry then scanned using the Immu-
noCapture software version 64 on a CTL Immunospot
analyser. The spots were counted using pre-established set-
tings in ImmunoSpot version 50 software. For determina-
tion of frequencies of antigen-specific memory B cells,
background responses were subtracted from the antigen-
specific responses. A positive ELISPOT response was
defined when the antigen-specific response was at least
five spots per 1 million PBMCs and at least twofold the
background response, as defined elsewhere [25].
Statistical analysis
Paired comparison of frequencies of memory B cells
within individuals at different time-points was performed
using Wilcoxon’s signed-rank test. Other comparisons of
frequencies of memory B cells between groups were per-
formed using Wilcoxon’s rank-sum test. Correlations
between frequencies of memory B cells and concentra-
tions of plasma antibodies were determined using Spear-
man’s correlation. Fisher’s exact test was used to check
for associations between memory B cell response and
antibody response. McNemar’s test of paired proportions
was used to evaluate response within individuals at differ-
ent time-points. Differences were considered significant if
P< 005. All statistical analyses were performed using
STATA version 13 (StataCorp, College Station, TX, USA).
Results
Participant characteristics
The characteristics of the 35 children in the memory B
cell substudy are shown in Table 1. Subjects’ median age
was 20 months and 54% were female. All children had
received at least one dose of pentavalent immunization
(against diphtheria, tetanus, pertussis, H. influenzae type
b and hepatitis B) in the first year of life, while 91.4%
had received all three recommended doses. Nasopharyn-
geal carriage was assessed in the parent study. Among
these substudy participants, there was a decline in overall
pneumococcal carriage from 886% (31 of 35) at day 0 to
714% (25 of 35) at day 180. There was also a reduction
in carriage of vaccine-type pneumococci from 429% (15
of 35) at day 0 to 257% (nine of 35) at day 180. The car-
riage rate of non-vaccine serotypes remained unchanged
at 457% (16 of 35). These findings are consistent with
the patterns observed in the parent study [21].
Antigen-specific immune responses
IgG levels against the vaccine serotypes were determined
in the parent study [21]. Among substudy participants,
PHiD-CV induced increases in the proportions of partici-
pants attaining the putative protective threshold of 035
lg/ml of anti-capsular IgG against all tested pneumococ-
cal capsular polysaccharides after the first and second
doses, consistent with findings of the parent study (Table
2) [26,27]. To a lesser extent, PHiD-CV also induced
increases in proportions of participants that had detecta-
ble memory B cells against some of the pneumococcal
antigens. The proportions of children with memory B
cells against serotypes 1, 19F and 23F at day 210 (after
the two doses of PHiD-CV) and serotypes 1 and 19F at
day 30 (after the first dose of PHiD-CV) were signifi-
cantly higher when compared to respective proportions at
day 0. PHiD-CV did not alter significantly the propor-
tions of participants who had detectable memory B cells
against serotypes 6B and 14 (Table 2).
Frequencies of antigen-specific memory B cells at base-
line and after the first and second doses of PHiD-CV are
shown in Fig. 1. The highest baseline and vaccine-
induced frequencies of memory B cells were observed for
serotype 19F. After each dose of PHiD-CV, there was a
significant increase in the median frequency of memory B
cells against serotype 19F [day 0: 0 (interquartile range
IQR5 0–4); day 30: 15 (IQR5 0–28); day 210: 23
(IQR5 0–61)]. For serotype 14, the median frequency of
Table 1. Characteristics of the children who participated in the study
Characteristic Value
Total number 35
Median age (IQR) in months 20 (16–22)
Females (%) 19 (54%)
Median children in household (range) 3 (1–6)
Smokers in household (%) 11 (31%)
Received 3 doses of pentavalent vaccine 91.4%
Received at least 1 dose of pentavalent vaccine 100.0%
IQR5 interquartile range.
Paediatric B cell memory to PHiD-CV
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memory B cells did not change significantly after the first
dose of PHiD-CV, but increased significantly after the
second dose of PHiD-CV [day 0: 0 (IQR5 0–3); day 30:
0 (IQR)5 0–8; day 210: 5 (IQR5 0–21)]. A similar pat-
tern was observed for serotype 23F [day 0: 0 (IQR5 0–
3); day 30: 0 (IQR5 0–4); day 210: 3 (IQR5 0–14)].
Median frequency of memory B cells against serotype 1
was higher after the first and second doses of PHiD-CV
when compared with baseline [day 0: 0 (IQR)5 0–0); day
30: 5 (IQR5 0–10); day 210: 4 (IQR5 0–15)]. There was
no significant increase in the median frequency of mem-
ory B cells against serotype 6B after either dose of PHiD-
CV [day 0: 0 (IQR5 0–0); day 30: 3 (IQR5 0–6); day
210: 3 (IQR5 0–12)]. Notably, these kinetics of memory
B cells differed from those of plasma antibodies, suggest-
ing independence in the generation of the two compart-
ments. There were significant increases in plasma
antibodies against all assessed serotypes after each dose of
PHiD-CV, with the highest increases being observed after
the first dose [21].
In PHiD-CV, the capsular polysaccharides for serotypes
18C and 19F are conjugated to tetanus toxoid and diph-
theria toxoid, respectively. PHiD-CV would therefore be
expected to boost pre-existing responses against diphthe-
ria toxoid and tetanus toxoid, components of diphtheria,
tetanus and acellular pertussis immunization (DTaP)
administered to children in the first year of life. The chil-
dren in this study also received a booster dose of DTaP
vaccine on day 60. We therefore determined the effect of
the study vaccination regimen on the memory B cell
responses against tetanus toxoid and diphtheria toxoid.
Administration of the first dose of PHiD-CV induced a
significant increase in the median frequency of memory B
cells against tetanus toxoid as measured on day 30 [day 0:
20 (IQR5 5–33) versus day 30: 45 (IQR5 10–119)].
However, administration of a booster dose of DTaP on
day 60 or a second dose of PHiD-CV on day 180 did not
further change the frequencies of memory B cells against
tetanus toxoid as measured on day 210 [day 30: 45
(IQR5 10–119) versus day 210: 58 (IQR5 24–127)]. A
similar effect was observed with regard to frequencies of
memory B cells against diphtheria toxoid [day 0: 11
(IQR5 1–33); day 30: 65 (IQR5 35–115); day 210: 66
(IQR5 38–166)] (Fig. 1). Notably, the vaccination sched-
ule did not alter significantly the proportions of partici-
pants that had detectable memory B cells against tetanus
toxoid and diphtheria toxoid, probably because the par-
ticipants had high pre-existing responses.
When the participants were stratified into two age
groups based on a cut-off of 18 months of age, 13 partic-
ipants were in the younger age group (median age5 16
months) whereas 22 were in the older age group (median
age5 22 months). There were no differences in propor-
tions of memory B cell responders for any serotype when
the older age group was compared with the younger age
group, with the exception of serotype 6B on day 30,
whereby the younger age group had a higher proportion
of responders (60 versus 0%, P< 001).
Relationship between plasma IgG and memory B cells
against pneumococcal capsular polysaccharides
Upon antigenic challenge, usually both quiescent memory
B cells and active antibody-secreting long-lived plasma
cells are generated [12]. Here, we checked for associations
between plasma antibodies and memory B cell responses
against the pneumococcal antigens. Due to the limited
sample that could be obtained from the participants and
the sampling times that were outside the period when
plasma cells would be expected in peripheral circulation,
we could not directly enumerate plasma cells [28]. We
chose to use previously measured plasma antibody con-
centrations as a proxy indicator of the number of plasma
cells generated.
Plasma antibody concentrations and the frequencies of
antigen-specific memory B cells correlated for serotype
19F on day 30 (after the first dose of PHiD-CV) and sero-
types 1, 6B and 19F on day 210 (after the second dose of
Table 2. Percentages of participants with serotype-specific immuno-
globulin (Ig)G responses and cultured B cell enzyme-linked immu-
nospot (ELISPOT) responses
IgG 035 lg/
ml
P-
value
ELISPOT
response
P-
value
Day 0
Serotype 1 3% 3%
Serotype 6B 29% 24%
Serotype 14 26% 21%
Serotype 19F 23% 21%
Serotype 23F 9% 13%
Tetanus toxoid 81%
Diphtheria toxoid 62%
Day 30
Serotype 1 91% <001 57% <001
Serotype 6B 66% <001 29% 025
Serotype 14 83% <001 36% 006
Serotype 19F 77% <001 61% 002
Serotype 23F 60% <001 24% 025
Tetanus toxoid 86% 100
Diphtheria toxoid 100%
Day 210
Serotype 1 97% <001 45% <001
Serotype 6B 97% <001 42% 024
Serotype 14 100% N/A 40% 006
Serotype 19F 91% <001 66% <001
Serotype 23F 91% <001 36% 002
Tetanus toxoid 94% 022
Diphtheria toxoid 83% 0.38
Statistical test use: McNemar’s test of paired proportions for day
0 versus day 30 and day 0 versus day 210. Differences were consid-
ered significant if P< 005.
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PHiD-CV) (Fig. 2). However, when the categorical data
on responders versus non-responders were considered,
there were no significant associations between antibody
responsiveness and memory B cell responsiveness, suggest-
ing minimal association between plasma antibodies and
memory B cells against pneumococcal capsular polysac-
charides upon vaccination with PHiD-CV (Fig. 3).
Relationship between baseline pneumococcal carriage
and anti-pneumococcal memory B cells after
vaccination
Some studies have reported serotype-specific antibody
hypo-responsiveness to pneumococcal antigens in individ-
uals that have nasopharyngeal carriage of the respective
Fig. 2. Relationship between plasma antibodies and memory B cells. Correlations between plasma antibodies and frequencies of memory B cells
against various pneumococcal capsular polysaccharides at different time-points are shown (top panel –day 30; bottom panel –day 210). Statistical
test: Spearman’s correlations. P-values< 005 were considered significant. Immunoglobulin (Ig)G antibody-secreting cells (ASC)/1 M peripheral
blood mononuclear cells (PBMCs), IgG antibody-secreting cells per 1 million PBMCs.
Fig. 1. Induction of memory B cells by pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV). Frequencies
of antigen-specific memory B cells against various pneumococcal capsular polysaccharides, tetanus toxoid (TT) and diphtheria toxoid (DT) are
shown in scatter dot-plots. Horizontal line represents median. Statistical test used: Wilcoxon’s signed-rank test. P-values< 005 were considered
significant. Immunoglobulin (Ig)G ASC/1M PBMCs, IgG antibody-secreting cells per 1 million peripheral blood mononuclear cells (PBMCs).
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serotypes at the time of vaccination [29,30]. To determine
if carriage at baseline affected the memory B cell response
to vaccination, we stratified children on the basis of their
carriage status on the day of enrolment and compared
the subsequent responses between the two groups. This
analysis was limited to serotype 19F, the only serotype
that was carried by more than two participants at base-
line, had detectable memory B cells in at least either car-
riers or non-carriers group and had data on frequencies
of memory B cells for the carrying participants in subse-
quent time-points. Baseline carriage of serotype 19F was
associated with a lower proportion of responders and
lower frequencies of memory B cells against the serotype
upon vaccination with PHiD-CV: when compared with
children who did not have carriage for serotype 19F at
day 0, the six children that had carriage had significantly
lower frequencies of memory B cells against serotype 19F
on day 30 [carriers: 0 (IQR5 0–0); non-carriers: 18
(IQR5 10–43)] and day 210 [carriers: 0 (IQR5 0–9);
non-carriers: 35 (IQR5 4–66)] (Fig. 4a). On day 30,
baseline serotype 19F carriage was associated with a sig-
nificantly lower proportion of participants with detectable
memory B cells against serotype 19F (non-carriers: 82%
versus carriers: 0%, P< 001), but a significant difference
was not observed on day 210 (non-carriers: 72% versus
carriers: 33%, P5 007) (Fig. 4b).
Fig. 3. Relationship between plasma antibodies and memory B cells. Number and proportion of participants who attained plasma
immunoglobulin (Ig)G 035 lg/ml and/or had detectable memory B cells against various pneumococcal capsular polysaccharides at different
time-points are shown (top panel: day 30; bottom panel: day 210). Statistical test: Fisher’s exact test. P-values< 005 were considered significant.
Enzyme-linked immunosorbent assay (ELISA)1: plasma IgG 035 lg/ml. Enzyme-linked immunospot (ELISPOT)1: antigen-specific
response 2 times of background response and 5 antibody-secreting cells (ASC)/1 M peripheral blood mononuclear cells (PBMCs).
Fig. 4. Relationship between baseline pneumococcal carriage and memory B cell responses after vaccination with pneumococcal non-typeable
Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV). (a) Frequencies of antigen-specific memory B cells against serotype 19F by
baseline pneumococcal carriage of serotype 19F. Horizontal line represents median. Statistical test used: Wilcoxon’s rank-sum test. P-values< 005
were considered significant. Immunoglobulin (Ig)G antibody-secreting cells (ASC)/1 M peripheral blood mononuclear cells (PBMCs). (b)
Proportions of study participants who had detectable memory B cells against serotype 19F on days 30 and 210 after stratifying on the basis of
baseline serotype 19F carriage. Statistical test used: Fisher’s exact test. P-values< 005 were considered significant.
D. M. Muema et al.
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Discussion
In this study, we report that vaccination of young chil-
dren with PHiD-CV induces memory B cells against select
pneumococcal capsular polysaccharides contained in the
vaccine and boosts the frequency of memory B cells
against two carrier antigens, diphtheria toxoid and teta-
nus toxoid. This suggests that vaccination may provide
long-lived protection against vaccine-type IPD.
Our findings are consistent with serological studies
showing that booster vaccination after primary vaccination
with PHiD-CV induces higher antibody responses than
primary vaccination alone, suggesting that PHiD-CV indu-
ces B cell memory upon primary vaccination [11,31,32].
Indeed, Clutterbuck et al. demonstrated that infants are
capable of generating serotype specific memory B cells
upon vaccination with the heptavalent pneumococcal con-
jugate vaccine [33]. Memory B cell responses to three of
the serotypes we studied – 1, 6B and 19F – were also
detected by van Westen et al. in Dutch children vaccinated
with PCV13 or PHiD-CV at 2, 3, 4 and 11 months of age
[34]. However, the absence of significant vaccine-induced
memory B cell responses against serotypes 6B and 14 in
our study, as opposed to the other serotypes in our study
and serotype 6B in the van Westen study, suggests that the
induction of memory B cells may vary by serotype and
geographical location, despite consistency in induction of
plasma antibodies. Alternatively, the increases in vaccine-
induced memory B cell responses against serotypes 6B and
14 may have reached statistical significance if the sample
size had been larger. These differences are unlikely to
undermine the immediate protection against the respective
serotypes, but it would be important to determine if they
result in varying long-term protection from disease.
The presence of some memory B cell responses against
all serotypes at baseline in some of the children suggested
that natural exposure or previous disease may have
induced the formation of memory B cells against the cap-
sular polysaccharides. In agreement, antibody responses
against pneumococcal capsular polysaccharides increase
upon natural exposure and are thought to contribute to
the age-dependent naturally acquired immunity to pneu-
mococcal disease [35]. However, we do not expect natural
exposure to have contributed significantly to the increase
in anti-pneumococcal responses during the study. First,
nasopharyngeal carriage of vaccine-type pneumococci
declined during the study period, reducing the possibility
of participants gaining natural antigen challenge. Further-
more, the older age group in this study did not have
higher proportions of responders, suggesting that the nat-
ural acquisition of responses could be slow and would
not have a significant impact on increase in immune
responses during the study period.
The prevalence and magnitude of baseline and vaccine-
induced memory B cell responses against the different
serotypes differed. Differences in sensitivity of the ELI-
SPOT assay for different serotypes are unlikely to explain
the variation, as PBMCs were cultured in the same cul-
ture conditions regardless of the ELISPOT-coating anti-
gen. However, pre-existing responses due to natural
exposure, nature of carrier protein and nature of the
polysaccharide itself could be important in determining
responses to each serotype. For instance, responses against
serotype 19F were much higher than those against any of
the other four serotypes tested, probably because serotype
19F is carried more commonly in the nasopharynx of
children in the studied community [22]. Memory B cell
responses against serotype 19F after vaccination with
PHiD-CV were also stronger than those of any other
serotype measured. The high baseline memory B cell
responses against serotype 19F suggest that children had
already been primed against serotype 19F, thereby leading
to higher vaccine-induced responses to the serotype com-
pared to other serotypes. In addition, as serotype 19F is
conjugated to diphtheria toxoid, an antigen that children
are exposed to through childhood pentavalent vaccination
series, the amount of prevaccination memory T cell help
available to serotype 19F-specific B cells may be higher
than for other antigens. Similarly, responses against teta-
nus toxoid and diphtheria toxoid were considerably
higher than those against any of the pneumococcal poly-
saccharides, probably because the children had received
three doses of the pentavalent vaccine in childhood in
addition to boosting by PHiD-CV and DTaP doses that
they received during the study. Furthermore, tetanus tox-
oid and diphtheria toxoid, being proteins, would be
expected to elicit T cell help more readily when compared
with polysaccharides, hence leading to stronger B cell
responses [36]. Similar differences between memory B
cells against tetanus toxoid, diphtheria toxoid and pneu-
mococcal capsular polysaccharides have been reported in
children elsewhere [33]. It would have been interesting to
determine if the vaccine induced similar memory B cell
responses against protein D of H. influenzae. This antigen
was not available; however, we would expect responses to
be similar to those induced against the other conjugating
proteins.
Both memory B cells and plasma cells are generated as
part of B cell responses. However, even though the num-
bers of memory B cells and plasma cells generated are
often correlated, the processes of generating the two B
cell subsets are independent [37]. This provides room for
discordance between the two subsets and raises the ques-
tion as to whether measuring circulating antibodies alone
provides a comprehensive picture of the B cell response,
especially the predicted longevity of B cell responses. The
differences in kinetics and absence of correlations between
memory B cells and plasma antibodies in this study are
in line with the independence between the two B cell sub-
sets and emphasize the importance of measuring memory
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B cells directly when determining the induction of mem-
ory by PHiD-CV.
We observed lower memory B cell responses against
serotype 19F in children who were carrying serotype 19F
in the nasopharynx at baseline. An inverse relationship
between carriage and serotype-specific IgG levels upon
vaccination with pneumococcal vaccines has been postu-
lated to be related to serotype-specific exhaustion of rele-
vant B cell clones that could blunt the antibody response
against the colonizing serotype [29,30]. Alternatively,
immunological priming through natural exposure could
have contributed to the observed effect. Pneumococcal
nasal challenge without resultant carriage has been shown
to induce mucosal IgG against protein antigens, implying
that priming and boosting of immune responses can
occur in the absence of active carriage as long as an indi-
vidual is exposed to the bacteria [38]. Such priming can
prevent nasopharyngeal carriage upon subsequent expo-
sure. In our study, it is probable that both carriers and
non-carriers had previously experienced natural exposure,
with the non-carriers eliciting better priming of systemic
B cell responses while also making better mucosal
responses that would prevent carriage. Such priming in
the children without nasopharyngeal carriage would
explain their better responses to the vaccine when com-
pared with children who had baseline carriage.
This study shows that PHiD-CV is capable of inducing
memory B cells against pneumococcal capsular polysaccha-
rides in children aged 12–24 months, which could contrib-
ute to a long-lasting protective effect against pneumococcal
disease. It would be important to assess if frequencies of
memory B cells correlate with persistence of protection.
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